Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.05Last Year’s EPS
-0.02Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 24, 2025
|% Change Since: -14.74%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in revenue growth and market penetration, particularly with the Decipher test. However, there are notable challenges, including a decline in product revenue and potential operational changes in the French subsidiary that could impact future performance and product availability.Company Guidance
In the Veracyte Fourth Quarter and Full Year 2024 Financial Results webcast, the company provided a robust guidance for 2025. Veracyte anticipates testing revenue to grow between 12% to 15% year-over-year, reaching $470 million to $480 million, with an adjusted EBITDA margin improvement of approximately 100 basis points. The company also highlighted significant growth metrics from 2024, including a 21% year-over-year increase in Q4 revenue to $119 million and a 23% rise in full-year revenue to $446 million. Testing revenue, which forms nearly 95% of their business, surged by 28% year-over-year, with Decipher volume growing 36% in 2024 and 45% in Q4 compared to the previous year. For 2025, Veracyte expects to continue its growth trajectory, driven by strategic initiatives such as the expansion of Decipher into metastatic populations, with anticipated volume benefits in the latter half of the year, and maintaining strong growth in the Afirma franchise with high-single-digit revenue growth. Additionally, the company is making strides in international expansion and advancing its MRD platform, while also managing a potential operational shift regarding its French subsidiary.Record Year for Veracyte
2024 was a record year with Q4 revenue totaling $119 million, marking a 21% year-over-year growth. Full-year total revenue reached $446 million, a robust growth of 23% year-over-year.
Testing Revenue Growth
Testing revenue, which accounts for almost 95% of the business, grew 28% year-over-year, with the fourth quarter showing a 24% increase over the prior year.
Decipher Test Performance
Decipher tests delivered more than 80,000 tests in 2024, a volume growth of 36%. Fourth quarter Decipher volume grew 45% year-over-year to a new record of more than 22,400 tests.
Adjusted EBITDA Margin
The company delivered a full year adjusted EBITDA margin of 20.6% and generated more than $70 million in cash.
---
VCYT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VCYT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 24, 2025 | $39.36 | $33.46 | -14.99% |
| Nov 06, 2024 | $36.59 | $37.34 | +2.05% |
| Aug 06, 2024 | $21.82 | $27.05 | +23.97% |
| May 07, 2024 | $21.03 | $20.12 | -4.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Veracyte (VCYT) report earnings?
Veracyte (VCYT) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Veracyte (VCYT) earnings time?
Veracyte (VCYT) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VCYT EPS forecast?
VCYT EPS forecast for the fiscal quarter 2025 (Q1) is 0.05.
---